Trial · NCT04006457
Participant flow45
How many started, completed or left each group, period by period.
1 to 20 of 45
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Main Study: Treatment Period 1 | STARTED | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | 449 | |
| Main Study: Treatment Period 1 | STARTED | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | 603 | |
| Main Study: Treatment Period 1 | STARTED | Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine | 0 | |
| Main Study: Treatment Period 1 | Treated | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | 447 | |
| Main Study: Treatment Period 1 | Treated | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | 603 | |
| Main Study: Treatment Period 1 | Treated | Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine | 0 | |
| Main Study: Treatment Period 1 | COMPLETED | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | 289 | |
| Main Study: Treatment Period 1 | COMPLETED | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | 332 | |
| Main Study: Treatment Period 1 | COMPLETED | Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine | 0 | |
| Main Study: Treatment Period 1 | NOT COMPLETED | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | 160 | |
| Main Study: Treatment Period 1 | NOT COMPLETED | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | 271 | |
| Main Study: Treatment Period 1 | NOT COMPLETED | Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine | 0 | |
| Main Study: Treatment Period 2 | STARTED | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | 289 | |
| Main Study: Treatment Period 2 | STARTED | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | 332 | |
| Main Study: Treatment Period 2 | STARTED | Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine | 0 | |
| Main Study: Treatment Period 2 | COMPLETED | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | 0 | |
| Main Study: Treatment Period 2 | COMPLETED | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | 0 | |
| Main Study: Treatment Period 2 | COMPLETED | Vaccine Sub-study: Tdap With or Without Meningococcal ACWY Vaccine | 0 | |
| Main Study: Treatment Period 2 | NOT COMPLETED | Main Study: Ritlecitinib 200 mg/ 50 mg QD (de Novo Participants) | 289 | |
| Main Study: Treatment Period 2 | NOT COMPLETED | Main Study: Ritlecitinib 50 mg QD (Roll-over Participants) | 332 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04006457/flow